Related Experiment Video
Updated: Aug 15, 2026
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Angiotensin-converting enzyme I/D polymorphism and diabetic peripheral neuropathy in type 2 diabetes mellitus: A
1Department of Endocrinology, West China Hospital of Sichuan University, Chengdu, Sichuan Province, China.
Background:
Several molecular epidemiological studies have been conducted to examine the association between angiotensin-converting enzyme (ACE) I/D polymorphism and diabetic peripheral neuropathy (DPN) risk. However, the conclusions remained controversial. We therefore performed this meta-analysis.
Methods:
PubMed and EMBASE were searched to identify case-control studies investigating the associations of ACE I/D polymorphism with risk of DPN. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of association between ACE I/D polymorphism and risk of DPN.
Results:
A total of seven case-control studies including 1316 cases and 1617 controls were included. ACE I/D polymorphism was associated with a significantly increased risk of DPN (OR=1.46, 95%CI 1.11-1.92, p=0.006, I(2)=48%). This result remained statistically significant when the adjusted ORs were combined (OR=1.84, 95%CI 1.14-2.99, p=0.01, I(2)=53%). In the subgroup of ethnicity, a significantly elevated risk was observed in Caucasians (OR=1.32, 95%CI 1.10-1.59, p=0.003, I(2)=43%).
Conclusions:
Our meta-analysis confirmed that ACE I/D polymorphism was associated with the risk of DPN.
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
01:21Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
01:26Type II Diabetes I: Introduction
01:24Type II Diabetes II: Pathophysiology
01:28Diabetic Nephropathy
01:22Diabetic Neuropathy